Safety, pharmacokinetics, and bioequivalence of vunakizumab injection, a specific dermatitis drug, in healthy Chinese volunteers: an open-label, randomized, two-stage, two-sequence cross-over study

OBJECTIVES: Vunakizumab (SHR-1314) is a novel IL-17A monoclonal antibody that has demonstrated great efficacy and safety in treating moderate-to-severe plaque psoriasis. This study aimed to evaluate the pharmacokinetics and safety of vunakizumab to healthy subjects following subcutaneous administration via a single 2 mL automatic injection (AI) pen compared to two 1 mL AI pen injections. METHODS: . RESULTS: were 109% and 107%, respectively. CONCLUSION: www.clinicaltrials.gov, identifier: NCT06182384.